How do I install the Ata Ppgl Avoid Fna Hnpgl skill?

Run npx skillmds@latest add dromlakhani/ata-ppgl-avoid-fna-hnpgl in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Ata Ppgl Avoid Fna Hnpgl safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Ata Ppgl Avoid Fna Hnpgl?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Ata Ppgl Avoid Fna Hnpgl free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Ata Ppgl Avoid Fna Hnpgl?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Ata Ppgl Avoid Fna Hnpgl by dromlakhani

Name: Ata Ppgl Avoid Fna Hnpgl
Rating: 4.2 (5 reviews)
Author: dromlakhani

Ata Ppgl Avoid Fna Hnpgl

Recommends against fine needle cytology for pathological diagnosis of head and neck paraganglioma due to its low accuracy and risk of misdiagnosis. Use when a clinician asks 'Should I perform fine needle cytology for suspected head and neck paraganglioma?' — triggers include suspicion of head and neck paraganglioma requiring pathological confirmation.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Avoid fine needle cytology for head and neck paraganglioma diagnosis

STEP 1 — Gather Information

Collect clinical presentation (neck mass, pulsatile tinnitus, cranial nerve palsies), high-resolution MRI/CT of skull base and neck, biochemical tests (plasma-free fractionated metanephrines, normetanephrines, 3-methoxytyramine), and assess for hereditary risk (family history, multifocality) to confirm suspicion of head and neck paraganglioma.

STEP 2 — Rule In / Rule Out

Is the lesion suspected to be a head and neck paraganglioma based on imaging and clinical features? If yes, proceed to avoid fine needle cytology; if no, consider fine needle cytology for alternative diagnoses (e.g., thyroid nodule, lymph node metastasis).

STEP 3 — Classify or Stratify

Subclassify the suspected head and neck paraganglioma as functional (elevated plasma-free metanephrines/normetanephrines or 3-methoxytyramine) or nonfunctional (normal biomarkers) to counsel on procedural risks.

STEP 4 — Decide

Do not perform fine needle cytology; rely on imaging characteristics, genetic testing (SDHD/SDHB), and definitive surgical pathology after resection for diagnosis.

Clinical Guardrails / Mimics / Pitfalls

Avoid fine needle cytology due to risk of hypertensive crisis or hemorrhage in functional tumors, high false-negative rates, and frequent misdiagnosis (e.g., thyroid paragangliomas mistaken for follicular neoplasms); do not substitute with core needle biopsy without hemodynamic precautions.

Concrete Clinical Example

A 48-year-old man presents with a left neck mass and pulsatile tinnitus. MRI shows a enhancing carotid body lesion. Plasma-free metanephrines and normetanephrines are normal. Suspected nonfunctional head and neck paraganglioma. Per guideline, fine needle cytology is avoided; instead, SDHD genetic testing is ordered and surgical resection is planned after alpha-blockade.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165

---name: ata-ppgl-avoid-fna-hnpgldescription: Recommends against fine needle cytology for pathological diagnosis of head and neck paraganglioma due to its low accuracy and risk of misdiagnosis. Use when a clinician asks 'Should I perform fine needle cytology for suspected head and neck paraganglioma?' — triggers include suspicion of head and neck paraganglioma requiring pathological confirmation.---# Avoid fine needle cytology for head and neck paraganglioma diagnosis## STEP 1 — Gather InformationCollect clinical presentation (neck mass, pulsatile tinnitus, cranial nerve palsies), high-resolution MRI/CT of skull base and neck, biochemical tests (plasma-free fractionated metanephrines, normetanephrines, 3-methoxytyramine), and assess for hereditary risk (family history, multifocality) to confirm suspicion of head and neck paraganglioma.## STEP 2 — Rule In / Rule OutIs the lesion suspected to be a head and neck paraganglioma based on imaging and clinical features? If yes, proceed to avoid fine needle cytology; if no, consider fine needle cytology for alternative diagnoses (e.g., thyroid nodule, lymph node metastasis).## STEP 3 — Classify or StratifySubclassify the suspected head and neck paraganglioma as functional (elevated plasma-free metanephrines/normetanephrines or 3-methoxytyramine) or nonfunctional (normal biomarkers) to counsel on procedural risks.## STEP 4 — DecideDo not perform fine needle cytology; rely on imaging characteristics, genetic testing (SDHD/SDHB), and definitive surgical pathology after resection for diagnosis.## Clinical Guardrails / Mimics / PitfallsAvoid fine needle cytology due to risk of hypertensive crisis or hemorrhage in functional tumors, high false-negative rates, and frequent misdiagnosis (e.g., thyroid paragangliomas mistaken for follicular neoplasms); do not substitute with core needle biopsy without hemodynamic precautions.## Concrete Clinical ExampleA 48-year-old man presents with a left neck mass and pulsatile tinnitus. MRI shows a enhancing carotid body lesion. Plasma-free metanephrines and normetanephrines are normal. Suspected nonfunctional head and neck paraganglioma. Per guideline, fine needle cytology is avoided; instead, SDHD genetic testing is ordered and surgical resection is planned after alpha-blockade.**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165

Frequently asked questions